A Flagship VentureLabs Company

moderna

200 Tech Square

Cambridge, MA  02139

Tel: 617-714-6500


Leadership:
Stéphane Bancel
President and CEO


Website:
www.modernatx.com

moderna

Flagship Partners:  Noubar Afeyan, Doug Cole
Initial Investment: 
2010
Status: 
Private

Moderna is pioneering messenger RNA Therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn secreted or active intracellularly. This breakthrough platform addresses currently undruggable targets and offers a superior alternative to existing drug modalities for a wide range of disease conditions. Moderna has developed a broad intellectual property estate, including more than 250 patent applications covering novel nucleotide chemistries and drug compositions. The company plans to develop and commercialize its innovative mRNA drugs through a combination of strategic relationships as well as new formed ventures. Founded in late 2010 by Flagship VentureLabs, Cambridge-based Moderna is privately held and currently has strategic agreements with AstraZeneca and Alexion Pharmaceuticals.

Noubar Afeyan is Chairman.